Blood Res.  2019 Mar;54(1):4-6. 10.5045/br.2019.54.1.4.

Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies

• Oh SY
• Suh C

• KMID: 2451048
• DOI: http://doi.org/10.5045/br.2019.54.1.4

Abstract

No abstract available.

MeSH Terms

Korea*
Lymphoma*

Reference

1. Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol. 2007; 82:446–452.

2. Koh MS, Kim WS, Kim SJ, et al. Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. Int J Hematol. 2015; 102:420–425.

3. Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2012; 91:543–551.

4. Seo J, Kim WS, Kim JS, et al. Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Blood Res. 2017; 52:200–206.

5. Im S, Oh SY, Jo JC, et al. Pylori eradication refractory gastric MALToma and H. pylori negative gastric MALToma. In : CISL Annual Meeting Abstract 2018;

6. Lee H, Yang B, Nam B, et al. Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. J Thorac Cardiovasc Surg. 2017; 154:342–349.

7. Oh SY, Kim WS, Kang HJ, et al. Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. Ann Hematol. 2018; 97:1851–1857.

8. Han JJ, Kim TM, Jeon YK, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol. 2015; 94:575–581.

9. Kim SY, Yang SW, Lee WS, et al. Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. Oncotarget. 2017; 8:68583–68590.

10. Oh SY, Kim WS, Kim JS, et al. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2010; 89:563–568.